The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
Principal Investigator: Juan Gimenez, MD
|Full Protocol Title||A Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to The Liver (RETNET): A Phase 2 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-Eluting Bead Chemoembolization of Neuroendocrine Liver Metastases|
|Sponsor||Abramson Cancer Center of the University of Pennsylvania|
|Change in Care||Participating may change your care|